J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...

Fifth Third Wealth Advisors LLC boosted its stake in Sanofi (NASDAQ:SNY – Free Report) by 27.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission.

DelveInsight's“Bullous Pemphigoid Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bullous Pemphigoid, historical and forecasted epidemiology as ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National Medical Products Administration (NMPA), which announced its approval the same day.

Sanofi India Ltd. key Products/Revenue Segments include Pharmaceutical Products ... Company has reported net profit after tax of Rs 82.19 Crore in latest quarter.The company’s top management includes ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation ...

The revamp is the first major action by recently-appointed chief executive Olivier Brandicourt, who took the top job ... bundles Sanofi's generic medicines and older products still in patent ...

It sells products through independent distributors primarily in India.Sanofi India's products viz. Lantus Combiflam Amaryl and Allegra feature in the top 100 pharmaceutical brands in India. The ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...